Bicara Therapeutics (NASDAQ:BCAX) Given Buy Rating at BTIG ResearchDefense World · 5 days ago
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire · Oct 5, 2026
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire · Sep 3, 2026
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire · Aug 14, 2026
Dimensional Fund Advisors LP Increases Stock Position in Bicara Therapeutics Inc. $BCAXDefense World · Aug 14, 2026
Bicara Therapeutics: My Optimism Is Building Despite Recent Market HeadwindsSeeking Alpha · Aug 12, 2026Bicara Therapeutics Inc., a biopharmaceutical firm in the clinical development phase, is headquartered in Boston, Massachusetts. Established in 2018, the company specializes in creating innovative, dual-action treatments specifically for solid tumors. At the forefront of their pipeline is ficerafusp alfa, a unique antibody designed to tackle solid cancers.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 11, 2026 | -$0.82 | -$0.82 | Miss |
| May 11, 2026 | -$0.64 | -$0.93 | Miss |
| Mar 26, 2026 | -$0.72 | -$0.68 | Beat |
| Nov 10, 2025 | -$0.55 | -$0.67 | Miss |
| Aug 12, 2025 | -$0.54 | -$0.50 | Beat |
| May 13, 2025 | -$0.40 | -$0.68 | Miss |